Screening assays often use whole cells to evaluate the effect of potential drug candidates, or other experimental stimuli, on various aspects of cell health, such as viability, growth, cytotoxicity, apoptosis, cell cycle, protein expression, intracellular signaling, and more.
These complex assays generate large amounts of biological and chemical information, which helps researchers discover the most effective drugs more efficiently, getting flawed compounds to fail fast. Screening assays can be used at nearly all stages of the drug discovery process, including target evaluation, lead identification, lead optimization, and early safety assessments.
Once a biochemical or cell-based assay has been developed successfully, the lead identification, or screening, process begins. Primary screens identify hits. Subsequently, confirmation screens and counter screens identify leads out of the pool of hits. This is commonly referred to as the hit-to-lead process.
Molecular Devices provides one of the widest ranges of bioanalytical systems to support drug discovery screening efforts--from target evaluation through to early safety assessments. We deliver high performance at an affordable price per data point across a full range of detection technologies, including fluorescence, luminescence, UV/Vis absorption, impedance, bright-field, and voltage/current.
Please select among the links below to learn more about screening assays and how specific product lines and families can support the success of your screening efforts based on your particular focus.